Company Overview and News

6
CI / Cigna Corp. CIGNA CORPORATION FORM 425 (Prospectus)

2h sec.gov
Filed by Cigna Corporation Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
CI

15
Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?

11h zacks
Express Scripts Holding Company (ESRX - Free Report) is scheduled to report second-quarter 2018 results on Aug 1, after the market closes. Solid performance by the Pharmacy Benefit Management segment (“PBM”) is likely to drive the company’s top line. However, the company is getting acquired by Cigna Corporation by the end of 2018.
ATHTF BIO.B BIO KDP DXCM WBA BAX ANTM CI ANTX

6
CI / Cigna Corp. CIGNA CORPORATION FORM 425 (Prospectus)

2018-07-19 sec.gov
Filed by Cigna Corporation Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
CI

6
CI / Cigna Corp. CIGNA CORPORATION FORM 425 (Prospectus)

2018-07-19 sec.gov
Filed by Cigna Corporation Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12
CI

15
Trump's Drug-Price Push Butts Into Two Megadeals - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CI CVS AET

10
UnitedHealth second quarter medical costs miss estimates, shares slide

2018-07-17 channelnewsasia
UnitedHealth Group Inc , the largest U.S. health insurer, reported a rise of nearly 28 percent in quarterly profit on Tuesday, driven by growth across its businesses.
ATHTF ANTM CI HUM UNH ANTX

10
Zacks.com featured highlights include: Cigna, American Financial, CBRE, First American and Allegion

2018-07-17 zacks
Chicago, IL – July 17, 2018 - Stocks in this week’s article Cigna Corporation (CI - Free Report) , American Financial Group, Inc. (AFG - Free Report) , CBRE Group, Inc. (CBRE - Free Report) , First American Corp. (FAF - Free Report) and Allegion PLC (ALLE - Free Report) .
WFCNP DAR AFGE MS.PRE WFC.PRL AFA MS.PRF WFC.PRJ MS.PRG AFGH MS.PRA WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN CI WFC.PRY MS WFC.PRX WFC.PRW CBRE WFC.PRV WFC WFC.WS AFW SGH AFG CBG MS.PRI MS.PRK

6
CI / Cigna Corp. DEFM14A

2018-07-16 sec.gov
TABLE OF CONTENTS
CI

6
5 GARP Stocks for a Winning Portfolio

2018-07-16 investorplace
Growth at a reasonable price, or GARP, provides an excellent opportunity for investors who are interested in raking in healthy returns. It helps an investor gain exposure to stocks that have impressive prospects and are undervalued.
AFG AFW CBG AFGE ALLE FAF AFA CI AFGH CBRE

6
5 New Strong Buy Stocks for July 16th

2018-07-16 investorplace
Cigna Corporation (NYSE:CI): This health services organization has seen the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days.
JILL ENLK TX CI

6
New Strong Buy Stocks for July 16th

2018-07-16 zacks
Cigna Corporation (CI - Free Report) : This health services organization has seen the Zacks Consensus Estimate for its current year earnings increasing 0.1% over the last 60 days.
ENLK CI

10
5 GARP Stocks for a Winning Portfolio

2018-07-16 zacks
Growth at a reasonable price, or GARP, provides an excellent opportunity for investors who are interested in raking in healthy returns. It helps an investor gain exposure to stocks that have impressive prospects and are undervalued. Unlike a blend strategy, a portfolio that uses GARP investing is expected to have stocks that offer the best of both value and growth investing. GARP Metrics – Mix of Growth & Value Metrics The GARP strategy seeks to offer an ideal investment by utilizing the best features of both value and growth investing.
AFG AFW CBG NTRS GTT NTRSP AFGE AFA CI AFGH CBRE

165
Amazon Hastens Retail Pharma's Last Stand

2018-07-15 seekingalpha
Amazon continues to startle markets with its market performance to date, leaping almost 52% through Friday's market close.
BRK.A ABC KR RAD WBA DTK CI CVS AET WMT ESRX

16
Wall Street Resumes Rally: 5 Triple-Play Miracle Stocks to Buy

2018-07-13 zacks
Wall Street resumed its rally after a dull Wednesday, following Trump’s threat to slap 10% tariff on another $200 billion in Chinese goods. The tension seems to be cooling down now on signals that the United States and China are willing to restart their trade talks to evade a full-blown trade war. As such, the technology surge has propelled the NASDAQ to a record high powered by Facebook (FB - Free Report) , Microsoft (MSFT - Free Report) and Amazon (AMZN - Free Report) .
CRZO FB PAG CAT MSFT CI SAM NCS GMS

8
Cigna Is Undervalued - Cramer's Lightning Round (7/12/18)

2018-07-13 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, July 12.
NEE.PRI LRCX NEE.PRJ NEE.PRC NEE.PRQ NEE.PRR CI SQM NEE

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to CI / Cigna Corp. on message board site Silicon Investor.

NanoViricides - Nanobiotechnology Laughter is the Best Medicine - Tell us a joke
NNVC - NanoViricides, Inc. The *NEW* Frank Coluccio Technology Forum
Nanoviricides - The Other Board The Financial Collapse of 2001 Unwinding
Socialized Education - Is there abetter way? Cisco Systems, Inc. (CSCO)
The Judiciary C (Citigroup)
CUSIP: 125509109